JP2023536974A5 - - Google Patents
Info
- Publication number
- JP2023536974A5 JP2023536974A5 JP2023507767A JP2023507767A JP2023536974A5 JP 2023536974 A5 JP2023536974 A5 JP 2023536974A5 JP 2023507767 A JP2023507767 A JP 2023507767A JP 2023507767 A JP2023507767 A JP 2023507767A JP 2023536974 A5 JP2023536974 A5 JP 2023536974A5
- Authority
- JP
- Japan
- Prior art keywords
- rnai oligonucleotide
- ome
- pharmaceutical composition
- sense strand
- galnac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024034617A JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061676P | 2020-08-05 | 2020-08-05 | |
| US63/061,676 | 2020-08-05 | ||
| US202063074779P | 2020-09-04 | 2020-09-04 | |
| US63/074,779 | 2020-09-04 | ||
| PCT/US2021/071109 WO2022032288A1 (en) | 2020-08-05 | 2021-08-05 | Compositions and methods for inhibiting lpa expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034617A Division JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536974A JP2023536974A (ja) | 2023-08-30 |
| JP2023536974A5 true JP2023536974A5 (enExample) | 2023-11-16 |
| JP7476422B2 JP7476422B2 (ja) | 2024-04-30 |
Family
ID=77519885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507767A Active JP7476422B2 (ja) | 2020-08-05 | 2021-08-05 | Ｌｐａ発現を阻害するための組成物及び方法 |
| JP2024034617A Active JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024034617A Active JP7805386B2 (ja) | 2020-08-05 | 2024-03-07 | Ｌｐａ発現を阻害するための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12435336B2 (enExample) |
| EP (1) | EP4192954A1 (enExample) |
| JP (2) | JP7476422B2 (enExample) |
| KR (2) | KR20250077604A (enExample) |
| CN (1) | CN116323943A (enExample) |
| AU (2) | AU2021320550B2 (enExample) |
| BR (1) | BR112023001957A2 (enExample) |
| CA (1) | CA3185348A1 (enExample) |
| IL (1) | IL300338A (enExample) |
| MX (1) | MX2023001538A (enExample) |
| TW (2) | TW202535432A (enExample) |
| WO (1) | WO2022032288A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435336B2 (en) | 2020-08-05 | 2025-10-07 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting LPA expression |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| EP4450624A4 (en) * | 2021-12-16 | 2025-03-26 | Tuojie Biotech (Shanghai) Co., Ltd. | LPA-TARGETTING SIRNA AND CONJUGATE |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| US20230374522A1 (en) * | 2022-04-15 | 2023-11-23 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating scap activity |
| IL318877A (en) * | 2022-08-11 | 2025-04-01 | Sirius Therapeutics Inc | Polynucleic acid molecules for inhibiting LP(A) expression, pharmaceutical compositions and uses thereof |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| WO2024112865A1 (en) | 2022-11-23 | 2024-05-30 | Eli Lilly And Company | Method of synthesizing 4'-phosphate analog nucleotide phosphoramidite |
| KR20250099265A (ko) | 2022-11-23 | 2025-07-01 | 일라이 릴리 앤드 캄파니 | 표적화 리간드-접합된 뉴클레오티드 포스포르아미다이트의 합성 방법 |
| KR20250124879A (ko) | 2022-12-22 | 2025-08-20 | 일라이 릴리 앤드 캄파니 | 올리고뉴클레오티드 단편 및 이를 사용하여 rnai 작용제를 제조하는 방법 |
| WO2024151937A1 (en) | 2023-01-13 | 2024-07-18 | Eli Lilly And Company | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |
| CN121358859A (zh) * | 2023-03-20 | 2026-01-16 | 维乎医疗有限公司 | 用于治疗心血管疾病的lpa基因的基于切口酶的体内编辑 |
| WO2024260380A1 (zh) * | 2023-06-20 | 2024-12-26 | 施能康医药科技(苏州)有限公司 | 靶向脂蛋白a的核酸及其用途 |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| WO2025087442A1 (zh) * | 2023-10-27 | 2025-05-01 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| WO2025117709A2 (en) * | 2023-11-29 | 2025-06-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting lp(a) and uses thereof |
| WO2025119212A1 (zh) * | 2023-12-05 | 2025-06-12 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| TW202546233A (zh) * | 2024-02-05 | 2025-12-01 | 美商靖因藥業（上海）有限公司 | 用於抑制ｌｐ（ａ）或ａｐｏｃ３之表現的多核酸分子、醫藥組合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
| US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
| ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
| CA2429814C (en) | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20050159378A1 (en) | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA) |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| WO2007030167A1 (en) | 2005-09-02 | 2007-03-15 | Nastech Pharmaceutical Company Inc. | Modification of double-stranded ribonucleic acid molecules |
| DK2341943T3 (en) | 2008-09-22 | 2019-02-25 | Dicerna Pharmaceuticals Inc | COMPOSITIONS AND METHODS OF SPECIFIC INHIBITION OF DSRNA REPRINT WITH MODIFICATIONS |
| US8691971B2 (en) | 2008-09-23 | 2014-04-08 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference |
| KR101728655B1 (ko) | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| EP2928877B1 (en) | 2012-12-06 | 2020-01-22 | Merck Sharp & Dohme Corp. | Disulfide masked prodrug compositions and methods |
| CA2950960A1 (en) | 2014-06-06 | 2015-12-10 | Solstice Biologics, Ltd. | Polynucleotide constructs having bioreversible and non-bioreversible groups |
| DK3569711T3 (da) | 2014-12-15 | 2021-02-22 | Dicerna Pharmaceuticals Inc | Ligandmodificerede dobbeltstrengede nukleinsyrer |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| HUE059718T2 (hu) | 2016-09-02 | 2022-12-28 | Dicerna Pharmaceuticals Inc | 4'-foszfát analógok és azokat tartalmazó oligonukleotidok |
| HRP20230127T1 (hr) | 2017-11-13 | 2023-03-31 | Silence Therapeutics Gmbh | Nukleinske kiseline za inhibiranje ekspresije lpa u stanici |
| UY38003A (es) * | 2017-12-12 | 2019-06-28 | Amgen Inc | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas |
| MX2022007005A (es) * | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
| US12435336B2 (en) | 2020-08-05 | 2025-10-07 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting LPA expression |
-
2021
- 2021-08-05 US US18/040,302 patent/US12435336B2/en active Active
- 2021-08-05 CA CA3185348A patent/CA3185348A1/en active Pending
- 2021-08-05 BR BR112023001957A patent/BR112023001957A2/pt unknown
- 2021-08-05 MX MX2023001538A patent/MX2023001538A/es unknown
- 2021-08-05 AU AU2021320550A patent/AU2021320550B2/en active Active
- 2021-08-05 TW TW114118397A patent/TW202535432A/zh unknown
- 2021-08-05 TW TW110128888A patent/TWI886314B/zh active
- 2021-08-05 IL IL300338A patent/IL300338A/en unknown
- 2021-08-05 KR KR1020257016689A patent/KR20250077604A/ko active Pending
- 2021-08-05 EP EP21762318.0A patent/EP4192954A1/en active Pending
- 2021-08-05 JP JP2023507767A patent/JP7476422B2/ja active Active
- 2021-08-05 KR KR1020237006019A patent/KR102812602B1/ko active Active
- 2021-08-05 WO PCT/US2021/071109 patent/WO2022032288A1/en not_active Ceased
- 2021-08-05 CN CN202180058046.7A patent/CN116323943A/zh active Pending
-
2024
- 2024-03-07 JP JP2024034617A patent/JP7805386B2/ja active Active
- 2024-08-16 US US18/807,591 patent/US12252691B2/en active Active
-
2025
- 2025-08-04 US US19/290,213 patent/US20260071219A1/en active Pending
- 2025-10-17 AU AU2025252633A patent/AU2025252633A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023536974A5 (enExample) | ||
| JP2024081668A5 (enExample) | ||
| JP2023518409A5 (enExample) | ||
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| CN113164509B (zh) | 用于抑制17β-HSD 13型(HSD17B13)表达的RNAi试剂、其组合物和使用方法 | |
| TWI826365B (zh) | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 | |
| JP2022515193A5 (enExample) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JP2022553348A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| JP2023530461A5 (enExample) | ||
| JP2023538284A5 (enExample) | ||
| JP2024514880A5 (enExample) | ||
| JP2020529197A5 (enExample) | ||
| TW202113079A (zh) | 經修飾之間隙子寡核苷酸及其使用方法 | |
| JP2024535888A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JP2018525030A5 (enExample) | ||
| JP2024516356A5 (enExample) | ||
| JP2023519246A5 (enExample) | ||
| JP2023506258A5 (enExample) | ||
| CA2357950C (en) | Therapeutic phosphodiesterase inhibitors | |
| JP2022520986A5 (enExample) | ||
| IL295086A (en) | Compositions and methods for inhibiting expression of hmgb1 |